Published 3 days ago • loading... • Updated 2 days ago

Tirzepatide improves kidney, cardiovascular function in patients with obesity and HFpEF

Summary by Medical Xpress

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to featured clinical research presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in JACC.

6 Articles

All

Left

Center

Right

News Medical

Center

Tirzepatide improves kidney, cardiovascular function in patients with obesity and HFpEF

2 days ago·United States

Read Full Article

European Medical Journal

Could gene therapy transform heart failure treatment?

A gene therapy for heart failure with preserved ejection fraction (HFpEF) has shown promising early results.

2 days ago

Read Full Article

bariatricnews.net

SUMMIT: Tirzepatide benefits people with obesity, kidney disease and heart failure

Tirzepatide improves kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to the outcomes of the SUMMIT Trial presented at the American College of Cardiology's Annual Scientific Session.The overall rate of cardiovascular death or worsening heart failure, the trial's primary endpoint, was higher in the 60% of study participan…

2 days ago

Read Full Article

Dataemia

Tirzepatide improves outcomes in HFpEF, obesity regardless of kidney function

March 31, 2025 2 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: The clinical benefits of tirzepatide in patien…

2 days ago

Read Full Article

Managed Healthcare Executive

Positive Results for Tirzepatide in Those With the Cardiovascular-Kidney-Metabolic Triad

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with chronic kidney disease as those without it, and there are signals that it has benefits for renal function.

3 days ago

Read Full Article